Cargando…

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey

BACKGROUND: Although women account for a growing proportion of the oncology workforce, there is evidence they are under-represented in leadership roles. To gain further insights into this issue and extend understanding of gender challenges, the European Society for Medical Oncology Women for Oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banerjee, Susana, Dafni, Urania, Allen, Tamara, Arnold, Dirk, Curigliano, Giuseppe, Garralda, Elena, Garassino, Marina Chiara, Haanen, John, Hofstädter-Thalmann, Eva, Robert, Caroline, Sessa, Cristiana, Tsourti, Zoi, Zygoura, Panagiota, Peters, Solange
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157518/ https://www.ncbi.nlm.nih.gov/pubmed/30273420 http://dx.doi.org/10.1136/esmoopen-2018-000422

Ejemplares similares

Report on the status of women occupying leadership roles in oncology
por: Hofstädter-Thalmann, Eva, et al.
Publicado: (2018)

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
por: Berghoff, A.S., et al.
Publicado: (2021)

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
por: Garrido, P., et al.
Publicado: (2021)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

Nachwuchsförderung durch die European Society for Medical Oncology (ESMO): Erfahrungen aus dem ESMO Young Oncologist Committee (YOC)
por: Oing, Christoph, et al.
Publicado: (2020)

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020)

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
por: Linardou, H., et al.
Publicado: (2023)

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
por: Curigliano, G., et al.
Publicado: (2020)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022)

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
por: van Halteren, H.K., et al.
Publicado: (2022)

COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
por: Castelo-Branco, L., et al.
Publicado: (2022)

Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions
por: Rauh, Stefan, et al.
Publicado: (2018)

Twelve ESMO Congress 2022 breakthroughs: practicing oncologists’ perceptions and potential application on presented data
por: van Halteren, H.K., et al.
Publicado: (2023)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
por: Pentheroudakis, G., et al.
Publicado: (2022)

Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic
por: Krech, R., et al.
Publicado: (2023)

Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
por: Rolfo, Christian, et al.
Publicado: (2016)

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
por: Garassino, M.C., et al.
Publicado: (2021)

ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies
por: Colombo, Ilaria, et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
por: Cortellini, Alessio, et al.
Publicado: (2022)

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases
por: Martin, P., et al.
Publicado: (2023)

LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases
por: Romano, E., et al.
Publicado: (2022)

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
por: Colombo, Nicoletta, et al.
Publicado: (2016)

Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period
por: Lazor-Blanchet, C., et al.
Publicado: (2022)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

Learnings from the forced transition of an industry supported educational programme for young experts in urology and oncology from face-to-face to digital during the COVID-19 pandemic
por: Weisshardt, Ina, et al.
Publicado: (2022)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
por: Banerjee, S., et al.
Publicado: (2021)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

EFPIA Guideline on a Quality Framework of Principles in Lifelong Learning in Healthcare
por: Hofstädter-Thalmann, Eva, et al.
Publicado: (2022)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021)

Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab
por: Willis, Scooter, et al.
Publicado: (2018)

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
por: Lim, K.H.J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2etnnntaq52l3nate5bn4t19ls